Status of anaplastic lymphoma kinase (ALK) in malignant mesothelioma

Serena Varesano, Claudio Leo, Simona Boccardo, Sandra Salvi, Mauro Truini, Paola Ferro, Franco Fedeli, Pier Aldo Canessa, Paolo Dessanti, Maria Pia Pistillo, Silvio Roncella

Research output: Contribution to journalArticlepeer-review


Background: Malignant mesothelioma (MM) is a particularly aggressive type of primary tumor, associated with exposure to asbestos, and characterized by high mortality. To date, there is no curative therapy for MM. The receptor anaplastic lymphoma kinase (ALK) was found to be mutated in many cases of cancer and used as a target in biological therapies. We investigated whether this pharmacological treatment could also be applicable to MM. Materials and Methods: The state of ALK was analyzed by immunohistochemistry and fluorescent in situ hybridization in 63 MM tissue specimens. Results: None of the 63 MM samples showed overexpression or translocation of ALK. Conclusion: Our preliminary data exclude the utility of analysis of the ALK gene in MM and suggest that ALK inhibitor therapy is not applicable to MM.

Original languageEnglish
Pages (from-to)2589-2592
Number of pages4
JournalAnticancer Research
Issue number5
Publication statusPublished - May 1 2014


  • Anaplastic lymphoma kinase
  • Crizotinib
  • Fluorescent in situ hybridization
  • Immunohistochemistry
  • Malignant mesothelioma
  • Targeted therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Status of anaplastic lymphoma kinase (ALK) in malignant mesothelioma'. Together they form a unique fingerprint.

Cite this